1. Home
  2. GBLI vs EDIT Comparison

GBLI vs EDIT Comparison

Compare GBLI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Indemnity Group LLC (DE)

GBLI

Global Indemnity Group LLC (DE)

N/A

Current Price

$28.60

Market Cap

398.7M

Sector

Finance

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$3.36

Market Cap

432.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GBLI
EDIT
Founded
2016
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
398.7M
432.8M
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
GBLI
EDIT
Price
$28.60
$3.36
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.30
AVG Volume (30 Days)
3.0K
2.3M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
5.13%
N/A
EPS Growth
N/A
37.50
EPS
1.05
N/A
Revenue
$450,098,000.00
$31,937,000.00
Revenue This Year
$14.23
N/A
Revenue Next Year
$9.68
N/A
P/E Ratio
$27.24
N/A
Revenue Growth
2.02
132.64
52 Week Low
$24.28
$1.66
52 Week High
$30.52
$4.54

Technical Indicators

Market Signals
Indicator
GBLI
EDIT
Relative Strength Index (RSI) 58.90 61.54
Support Level $27.66 $2.74
Resistance Level $29.16 $3.65
Average True Range (ATR) 0.89 0.20
MACD -0.02 0.06
Stochastic Oscillator 89.07 75.62

Price Performance

Historical Comparison
GBLI
EDIT

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: